Active substance
Distigmine
- SFDA 2
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| UBRETID | 5 mg | Tablet · Oral use | 20 Blister | SAR 13.40 | NCE · Prescription | Takeda Manufacturing Austria AG | Withdrawn by MAH · Not Marketed |
| UBRETID 0.5MG AMP | 0.5 mg | Injection · Intravenous use | 25 Ampoule | SAR 27.50 | NCE · Prescription | Takeda Manufacturing Austria AG | Withdrawn by MAH · Not Marketed |
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.